{"name":"Alkeus Pharmaceuticals, Inc.","slug":"alkeus-pharmaceuticals-inc","ticker":"","exchange":"","domain":"alkeus.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ALK-001 oral capsule","genericName":"ALK-001 oral capsule","slug":"alk-001-oral-capsule","indication":"Geographic atrophy secondary to age-related macular degeneration","status":"phase_3"}]}],"pipeline":[{"name":"ALK-001 oral capsule","genericName":"ALK-001 oral capsule","slug":"alk-001-oral-capsule","phase":"phase_3","mechanism":"ALK-001 is a retinoid that reduces toxic bisretinoid accumulation in the retina by inhibiting the visual cycle.","indications":["Geographic atrophy secondary to age-related macular degeneration","Stargardt disease","Other inherited retinal dystrophies"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQWDVVT0I3X1p5NmhLaFpnNkMyMzEtX3pYb3RQd25VamMzbnlwVWFyTFFvVk9NaHhrY0tDSzFzQy1xaGpJdmxmdWJ6TW9EUjdPZFNWODNremFrZjUxX2NxZWpFMVIza2JVUFdvWXExMTV4MXBHY2REeUN4bmtRSmhYSy0yWVcybHZUaWNESGFNc042LWhHcTd4N3E1RFZnOFFWU0xIT1Q5SFMwTGhNRk9tay00MlRzcjdHLUFBamJNSXZmTzV2V1RxekhqU3poSl9F?oc=5","date":"2026-02-25","type":"regulatory","source":"BioCentury","summary":"Rare disease spotlight: Stargardt’s first approval in sight as next-gen aims to restore vision - BioCentury","headline":"Rare disease spotlight: Stargardt’s first approval in sight as next-gen aims to restore vision","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNMUJ1MVB1V0NPM0Q1NlFHSFlmQk01Nmt3Y0p2dUFUOGJYY3lCaXI1QUg5a3hxbXFXTzRaUDFEWVNkcHQyNGdPa2VTQy1jSUgzUHpJQTQ1c0VKQS1EeXZ1bkxNa2VyZWZuTURWbVdSTnVqZkFJcHdma21KZU40VWhHc0dxM3NreTRQb0NhdnhWQ1MzdEM2YUM5LU5HZTJnWEF0VXNybkFvTktpek1FRDlRS2tMZHY3ZnB0a2pqZHNpb2hTTm9QbW1UdGZ5TGg0SWZJU2E2UW95RE5yNzVRelNfaWZiUUd2clJRaXVv?oc=5","date":"2025-12-02","type":"trial","source":"Citeline News & Insights","summary":"Belite Bio’s Tinlarebant Shines In Phase III Stargardt Disease Trial - Citeline News & Insights","headline":"Belite Bio’s Tinlarebant Shines In Phase III Stargardt Disease Trial - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNal9yb0poS19QYmQ1U3N3bGFzYXJ3VVFoNFZ1bFBEbWFTRGIwbmZOcVdqR0JaSWtsNjR1dVhjNzRaVFJLUzJBSDQtRUpha1VkNW9WSDdlY3pOd2FHeTRHXzhtUEZwMlJYSWFoWUhucWQ1eWdtTEkxNzR1MHlrSGpvUnBkZVE0ODlWQVpoRWhBS19iSUlXY3FsemVFd0xzV2RmOV91MUxSZ2NoWTFnNjFqQXF1QW83YzRTNDZlZ0FNYmZha1dGRjVNbzViMldQSXdyRXl6V1EtVmdRYlZOZHZuTnVQU2ZZR1NZQ0hqRmpuZkw1X09uRHMzd0duNlpOZlhULWMzRnVlajBBb3g0OWJYQnExeGNMc2ZqZHFuMld5YmFObkVMZFF0VXJLT3BpRVRFM3ZUS2Q4TGw4TDhLUUhGS1V4VU1kbS00Q0NR?oc=5","date":"2025-12-01","type":"pipeline","source":"GlobeNewswire","summary":"Geographic Atrophy Market to Surge Significantly During the - GlobeNewswire","headline":"Geographic Atrophy Market to Surge Significantly During the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxNS1pXS2lqVzQxaHhpc1pEZmY1NmJCOGhEUlJrOFoxcHVBMXNRVTFLdkZXbjFxVS1wTk9tRlUyakFFSi1QQk44TERaMnUtZDZLbFNQYl9tbkFrX3d4Qjl1V19OelYzLU1iMjRZWjFnQTZWUU9ta1JHNVlQS1kzTDZNamJCRVBoMVJLT2JodlV1T2JYVXBoRkxWcjlaQUpoS2xEUmhPRE91Rll6S0VWUWJ4V1k2UFg4eHI3ZWJONjg5M0hEWURsUGdjcTFRX1drR2ZuZEtFZlRqcUYxdHVQcHNLUFJHVllhTzh6S0N0Si04QUJwc3B0SU1vMVI1eUtQbFJrLXNiOENyWmIwcDIyTmZPM0RQSjM3OU9ucGxsN0c4MnR1elpUcjFaMWtTOFdySE5RTFZpY3d4WlphZnY0T29jZ1cyUEJocmpmd2hVU3ZR?oc=5","date":"2025-10-09","type":"trial","source":"GlobeNewswire","summary":"Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting, October 18-21 in Orlando - GlobeNewswire","headline":"Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data at the American Academy of Ophthalmology (AAO) 2025 ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxPcW1TSjBMRFZud25HMTNhV2VVUDM1Z2tXZUJpbEc1OTAtbjlOdWlIb3c3STFYM0Q1TUNkUW1NLXFGWlJTdmVWQjZ2VmtMRlVfTzYtSHNKLWY1cXgzRDI4Mm1YRjNZREdSNWpyVEticmk2U3FVU1Mxay1BcldvWmIxcGJLX0I0Qi1ORWJsNkJyZ19pQVVjbjMxaVFHNEFHNWhjTGQ0Q0ZmV1dib2h6NEtKTDV4RWdSb29TN1pLcGh3STlNaV9CNnNXSDBOTWVDNWNsNlZ1MFUzZFRKQ2dTQ21DZUIwZm4xTTJYcXlmd3VRWkdMcjRZNmVLZ3JoRzZmZUJ0NVlEQmNKa0Y4MDJPcGlxVjQ3X0FMSVp1Qm5wZHpuaXhuN2Nnbm0wQjlVWFJqMWlDdkFUYy1MaC1PM3pmcDN6cnk5aWU1aF9wbU9mT09Ndw?oc=5","date":"2025-08-07","type":"pipeline","source":"GlobeNewswire","summary":"Alkeus Pharmaceuticals Announces Presentation of Positive - GlobeNewswire","headline":"Alkeus Pharmaceuticals Announces Presentation of Positive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPOXotM2lEdXh3dEd4MUpKeTAxbGtIQXl4eEVXY3VUSzVQZHVENkpvLVVMV0x3WjZGX2NyM0JJdjZRT092ZlpNREVfdFhkN3BHUnlBX1g5ajRoeERkaWVtTTdBNHVFN25GUjI0aHNMR2plQU5lZjF3WC1ueHBkWlhncmJHZXpGZGl5T0RkTzZxdlRqV084b0pxR1B1RHVGTTNoWnVuSVRpZUgzblVrcXNpVzctQjhuNjV1TEEtZ1FYcmhaQjh5clpqdHRBTVZDZDhFeUw1ZUhSdUlJUWNVQlM4bw?oc=5","date":"2025-02-25","type":"pipeline","source":"GlobeNewswire","summary":"Alkeus Pharmaceuticals Announces Establishment of Scientific Advisory Board - GlobeNewswire","headline":"Alkeus Pharmaceuticals Announces Establishment of Scientific Advisory Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPSHJBMkpnTl9iVGZZb1lCNnc3TG5CeU4xR2V0Qno4eXJBUy1iT0x6cVF0bjBhRE0tWkN3blBmTkhfWjI1ZlZ0VVU3Q2llQ2FKaFFIWUpkamN6dXpGczV0VzVIV3Q2LXJZR1BKTklGSnlodDRBclZUV3lOdG9mdWNraW9NZTNDdEozRmw0bDFpdmlmR1AxYndTSmlzaHh5RzZyWUllNld0UFU0VHpKUk9TUHhWVzN5dk1vRk90am5jT0xYb2pDR1R6QURCSVdvdjk5Y2k0M3A1bFhHLVd2YnZWQU1nSDhRRG1BbE14U20yNmFZdC1CSG8yZ1psaTJ0UVhQSEhic21LV3l1TjdSb3ZzYlVZbVNQTHB0Vlc4QzQ0V1Azal9hY3FDMWFNRkpyX09NLUNWb3dCYlRSajlDVWFwQVJRNC0tVlRabFVUY0NrYzdkb0k?oc=5","date":"2025-01-09","type":"pipeline","source":"GlobeNewswire","summary":"Alkeus Pharmaceuticals Announces New Positive Interim - GlobeNewswire","headline":"Alkeus Pharmaceuticals Announces New Positive Interim","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxOWnFwcEFyaWluNXNacFJfeWQ2NVdsUjEzRG1YeS1TWDUzQ01vYzBtN1lSOHNZMGRjREktdEdBOWV6U2l6QUwtLTI0MVFpekxyTFM0NDZVSkJmN0RKSlZ5bWRDMnNCeWJjNGtER3hJaUE1YjdyVExDeEdEamd2Mi1LcncyTDBHdl9tdl9YWlRXSEh0ZERXVzRTMEkzbkY3V29CMmFVdW1uV2p3NHNkVmNXdE9aUDU1VGV4ZGVXeVpFVXVJY1dydjIxclA3MkFkeGlvem9SUjB0dlRFZlBlWXJ5NDFCalBpSmk5VkhpUl9fT3pHSUdGZGU1YTRhSzZwWnNMQUlCWkZLSXJGbE1mX1NZ?oc=5","date":"2024-11-19","type":"pipeline","source":"GlobeNewswire","summary":"Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire","headline":"Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPSEhpalI3UU81WlRROEwzTm50RlNsRlFZUm9LOW1Jczlza3ROdVdEblVfOUQwRmFuakcwN2t5N0ZERUIzNXAzcVJoMUZNS3diOWgxdjZwRmlyOHFhZ01TeEc4SlFKLXR6TDhLYW1wSmpwcXQ5TTYzTVhPNXhFWjJJNEEwRW1ITVBnMnlGcXZGRDQ0VDBHUWVDS01nYlVwMU11aU9HWnpVQzI5bHpldTRCM3pDZVB0SzVERXpiOTEtQnNneDFIODJPVkpfWnl5S3huMUxUb1Z3Q0lYWVQ5Um03Yk1HdFZnOHZ3a2M2LUU5S1JuQkMxNTNmQ25ZMW1Ld2RqNnAxR3VBdnRpY3c?oc=5","date":"2024-11-18","type":"regulatory","source":"Ophthalmology Times","summary":"Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease - Ophthalmology Times","headline":"Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQSWhCOXVmX01Wc3NwT2c1RGlIdzFTbl9Odmd4Uk14Qk1QZnZKS2FKUmNDdjVJakFoOHFySUoxanlEWVM4R2o0bTZmMUw3UWd3U2hwd011WE12bFY5eko3TWFqYWtQdUVFTEpVN0FaZFlfbjBHTEdZRFU1RW1kc0Rvc010TElQRmpmLTF2dHdVMUVGUHcyX1BwX1FWd2FrNVAzeWQyWjJBSFF6TFBzX0J3VUk0RXlHR1ItWTkwbVdDOGFadEY5bEQzdU5kZXljcjJPMkF3LWNUb19GUQ?oc=5","date":"2024-09-19","type":"trial","source":"Ophthalmology Times","summary":"Alkeus Pharmaceuticals announces results from the SAGA study of oral gildeuretinol in patients with GA - Ophthalmology Times","headline":"Alkeus Pharmaceuticals announces results from the SAGA study of oral gildeuretinol in patients with GA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNNExUYllpeVZtVi1VZDJ4OFBJeVdKR3NadDBsdUlOUVZFU2VLRHNuVFF0YWcyR2lmUEt2d21oOXdZSWVzcjd3LTctS1hObU1XNGNyc0J1a0JyckVNVWtaRkZsM25ObWMyNmhqd3p4OHhMTmpxMXFCSlBGaGMwbDRJWm5pZDZJdmhiZ05Xd3VyOA?oc=5","date":"2023-06-05","type":"pipeline","source":"BioPharma Dive","summary":"An unconventional drug startup lures Vertex founder Josh Boger back to biotech - BioPharma Dive","headline":"An unconventional drug startup lures Vertex founder Josh Boger back to biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPWnVCZVRacGpsNlJQNFladmlMN1VPbGZJODdYVXJhbUoxZ3BWN1V4VGF1VDN6UWJJaU5wX2laRnE5c0VpbG93SDJPZVpnUFNna0JXVVJudTVkYnhWZFpNSmNHeFJYQ0Q1R2thUkM3MkUtc2JJNG9tdEdKTWhQZHBRS0pfQVczcnhIazFBQ2NZNDJicWE2cjZVZlp2SQ?oc=5","date":"2021-07-14","type":"regulatory","source":"Ophthalmology Times","summary":"Breakthrough Therapy Designation granted by FDA for Alkeus Pharmaceuticals’ ALK-001 Stargardt disease treatment - Ophthalmology Times","headline":"Breakthrough Therapy Designation granted by FDA for Alkeus Pharmaceuticals’ ALK-001 Stargardt disease treatment","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}